Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | AGXT | P21549 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4440025 | 0.98 | KIF11 (0.48) | KIF11DHODHPTPN1AGXTHDAC4 | |
| SCHEMBL4440029 | 0.82 | KIF11 (0.48) | KIF11DHODHPTPN1AGXTHDAC4 | |
| SCHEMBL4441126 | 0.81 | AKR1C3 (0.49) | KIF11 | |
| SCHEMBL19561446 | 0.81 | DHODH (0.51) | KIF11DHODHPTPN1 | |
| SCHEMBL1825332 | 0.80 | CES2 (0.50) | MGLL | |
| SCHEMBL18434981 | 0.80 | HDAC8 (0.45) | DHODHPTPN1HDAC4PTPN5MGLL | |
| SCHEMBL30097986 | 0.79 | CES2 (0.53) | MGLL | |
| SCHEMBL1584197 | 0.79 | CES2 (0.48) | MGLL | |
| Hydrogen Sulfide SCHEMBL27914319 | 0.78 | HDAC8 (0.44) | DHODHPTPN1HDAC4PTPN5MGLL | |
| SCHEMBL26821713 | 0.78 | KIF11 (0.73) | KIF11DHODHPTPN1AGXTGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PPARA, PPARG, PPARD | KIF11 4491/4885DHODH 4189/4885PTPN1 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.